Immunosenescence (the aging immune system)

Immunosenescence is the age-related remodelling and decline of the immune system, and although it is not one of the twelve hallmarks of aging, it sits alongside their integrative tier — it is less a single root cause than a system-wide failure that both results from upstream damage and then accelerates it.^[1] Much of its story can be told through one cytokine — interleukin-15 (IL-15) — which turns out to be a central regulator of the immune cells that age worst, and a useful lens on why the body's defences fade and what, realistically, keeps them sharp.

How confident should you be

The decline itself — Strong. IL-15 as the organising mechanism — Moderate, and largely from cell and animal work. The centenarian finding — observational. Drugs and supplements — Weak, with a real Caution attached.

Two things on this page are solid: the immune system measurably deteriorates with age, and that deterioration feeds the same inflammation that drives age-related disease. The interpretive frame — that one cytokine, interleukin-15, ties it together — is a useful lens rather than a settled fact, and most of the evidence behind it is in cultured cells, mice and rats. The centenarian data is a snapshot of people who already aged well, not a demonstration that anything caused it. And the pharmacology section is about cancer drugs, evaluated in seriously ill patients under close monitoring — a setting that tells you very little about what they would do to a healthy person.

One note on the numbers below. Where a result is followed by a range in parentheses — a 95% confidence interval — that range is where the true effect most plausibly lies; when it spans zero, the result is compatible with no effect at all.

What breaks down

Strong for the description; the functional consequences are cohort-level associations.

The most consequential single event is thymic involution. The thymus — the organ that schools fresh T-cells — begins shrinking in early adulthood and is largely replaced by fat by the time most people reach their fifties. As its output of new naive T-cells dries up, the immune system is forced to lean on an ever-narrower pool of existing memory cells, leaving it slower to recognise threats it hasn't seen before — which is part of why vaccines work less well and new infections hit harder with age.^[2]

At the same time the surviving T-cells degrade in a characteristic way. The defining marker is loss of CD28, a molecule T-cells need for proper activation; as cells lose it they acquire the surface markers of senescence, divide poorly, and — like the senescent cells described under cellular senescence — stop doing useful work while pumping out inflammatory cytokines.^[3] Meanwhile the innate side weakens too: the cytotoxic power of natural killer (NK) cells, the body's first responders against virus-infected and pre-cancerous cells, falls with age, and low NK activity in older people tracks with higher infection and cancer risk.^[4] The net effect is a system that is simultaneously less protective and more inflammatory — the immune contribution to inflammaging, the chronic, low-grade, germ-free inflammation of older bodies covered under chronic inflammation.

IL-15: the cytokine that ties immune aging together

Moderate. The receptor biology is well established; the framing of IL-15 as the organising thread is an interpretation, and the anti-senescence effects below are in cultured cells.

If one molecule sits at the centre of immune aging, it is IL-15. It is the principal survival and growth signal for exactly the cells that fare worst with age — memory CD8⁺ T-cells and NK cells.^[5]

What makes IL-15 unusual is how it is delivered. Rather than being released freely into the blood — which would be dangerous for so potent an inflammatory signal — it is mostly handed over cell-to-cell: a producing cell holds IL-15 on its surface and presents it directly to a neighbouring lymphocyte, a mechanism called trans-presentation that keeps the signal local and tightly controlled.^[6] When that signal lands, it switches on a growth-signalling cascade and raises an anti-death protein, which together are what keep memory T-cells and NK cells alive.^[7]

IL-15 also pushes directly against T-cell aging. It sustains the activity of telomerase, the enzyme that maintains the protective caps on chromosomes whose erosion is covered under telomere attrition; in laboratory memory CD8⁺ T-cells, IL-15 minimises telomere loss across repeated divisions and helps preserve their replicative lifespan.^[8] In tumour-specific memory T-cells it can even turn down the cell-cycle brakes (p16, p21, p53) that enforce senescence, restoring their ability to divide.^[9] The catch — and it is the central catch of the whole topic — is that these are effects of appropriate IL-15 signalling. Too much, for too long, does the opposite, as the section below on the pulsatile principle explains.

NK cells and the clearing of senescent cells

Moderate as mechanism; the evasion tactics are cell and animal work.

One of the most important jobs of a youthful immune system is senolysis — physically finding and killing senescent cells before they accumulate. NK cells and cytotoxic T-cells are the main agents of this clean-up, and it is largely IL-15 that keeps them fit to do it.^[10] When NK function fades with age, senescent cells linger and their inflammatory secretions spread — the immune-surveillance failure that the cellular senescence article describes from the senescent cell's side.

Senescent cells do not go quietly. They actively evade immune clearance using tactics that look strikingly like a tumour's. They secrete an immunosuppressive signal that blunts the receptors NK cells use to recognise a target, and they shed soluble decoy versions of the very molecule those receptors look for, mopping up and exhausting them before the NK cell can make contact — effectively cloaking themselves.^[11] This is part of why simply "boosting" immunity is harder than it sounds: the targets fight back.

The centenarian paradox

Observational. A snapshot of people who already aged well — it cannot tell you what caused it.

A suggestive natural experiment comes from people who have aged exceptionally well. In a cross-sectional study of 30 people aged over 95 — most of them women — circulating IL-15 was higher than in either adults under 60 or people aged 60 to 89.^[12] Thirty people, measured once, two decades ago: suggestive, not settled. On its face that is a paradox: IL-15 is pro-inflammatory, so high levels ought to mean runaway inflammaging. And in a separate cohort, the T-cells of high-performing centenarians proliferated more on stimulation, and carried longer telomeres and more telomerase activity, than those of both low-performing centenarians and 67-to-83-year-old controls. The distinction matters — low-performing centenarians looked like the controls, so this is a property of aging well, not of reaching 100.^[13]

The resolution is that they run the opposing brake at the same time. Where ordinary aging tilts the balance toward the inflammatory helper T-cells, centenarians hold more of the regulatory T-cells that restrain them, and run high levels of the signals those cells use to damp inflammation down.^[14][15] The lesson is the same one that runs through the inflammaging article: exceptional immune aging is not about suppressing the immune system, but about pairing aggressive surveillance with an equally strong off-switch — precision and resolution, not blanket quiet.

The pulsatile principle, and why exercise is the lever

Moderate. The exhaustion result is in cultured human cells; the exercise half is a human meta-analysis.

The single most useful idea in this area is that IL-15 has to come in pulses. Brief, transient spikes rejuvenate immune cells; chronic, unremitting elevation exhausts them. When human NK cells are bathed continuously in IL-15, they initially ramp up but then suffer a metabolic collapse — fatty-acid oxidation falls, spare respiratory capacity disappears, and the cells lose their ability to kill.^[16] Overdriving the cell's main growth-and-nutrient pathway is the culprit: dialling the signal back down, or simply giving the cells a break between exposures, prevents the exhaustion.^[17] This is why chronically elevated IL-15 — from obesity, persistent viral infection, or continuous drug dosing — is harmful, while episodic spikes are not.

The body's natural way of generating those spikes is muscular work. Skeletal muscle is an endocrine organ, and during contraction it releases IL-15 as a myokine under the control of the cellular energy sensor AMPK; mice engineered to lack muscle AMPK lose this exercise-driven IL-15 and show accelerated skin aging — thinner dermis, less collagen — which low-dose IL-15 partly reverses.^[18] In humans, a meta-analysis of 15 studies in 411 people found that a single exercise session reliably spikes circulating IL-15 — a large effect (standardised mean difference 0.90, 95% CI 0.47–1.32) that held regardless of exercise type or how trained the participants were. Across 12 studies in 899 people, chronic training left resting IL-15 essentially unmoved (0.40, 95% CI −0.08 to 0.88 — a range that includes no effect).^[19] That is exactly the pulsatile pattern the biology calls for — and it dovetails with the muscle-derived "IL-6 paradox" already described under chronic inflammation and the broader case for resistance training.

What actually helps — the lifestyle levers

Exercise — Moderate. Energy balance — Weak (rat data). Sleep — Weak (inferred from the inflammaging evidence).

As with every hallmark, the evidence is strongest for the unglamorous interventions, and they work by keeping the whole body in good metabolic and inflammatory order rather than by targeting IL-15 directly.

Exercise, especially intense and varied. This is the best-supported lever, and the mechanism is clean: high-intensity intervals and heavy resistance training produce the transient IL-15 spikes that prime NK and memory T-cells, without the chronic elevation that exhausts them.^[20] Beyond the immune signal, muscle-derived IL-15 improves the muscle's own oxidative metabolism and glucose uptake.^[21]

Sensible energy balance — though the direct evidence here is animal. In rats, IL-15 signalling and its receptor become chronically over-expressed in fat tissue over the course of aging, which alongside tumour necrosis factor alpha degrades insulin signalling; lifelong calorie restriction — 40% in that experiment, across 36 animals — prevented the pattern.^[22] That is a mechanistic hint, not a human dosing recommendation, and 40% restriction is far beyond anything this site suggests. The framing is the same as in the chronic inflammation article: much of the benefit rides on fat loss and dietary quality, not on any schedule trick. One caveat-laden finding: among 61 amateur runners, those getting under 45% of their energy from carbohydrate had lower IL-15 levels — a single-cohort observation at a fairly ordinary intake, not a licence to carb-load.^[23]

Sleep. Adequate, regular sleep preserves the anti-inflammatory feedback that immune aging erodes, the same reasoning laid out for inflammaging; it is a genuine immune-maintenance input, not a recovery nicety.

The drug and supplement frontier

Weak, and a Caution. None of this is established for healthy adults, and the supplement end of it rests on single small trials, cell culture and animal work.

A great deal of money is chasing IL-15 pharmacologically, and the results are a useful illustration of why the pulsatile principle matters.

• IL-15 superagonists (N-803, formerly ALT-803) are engineered to deliver a strong, long-lasting IL-15 signal, and in cancer trials they have produced real responses — in a phase 1b trial pairing N-803 with nivolumab in metastatic lung cancer, 6 of 21 patients had a partial tumour response (29%, 95% CI 11–52), though that figure was worked out after the fact rather than as a prespecified endpoint. That trial also recorded no dose-limiting toxicities, and never reached a maximum tolerated dose.^[24] It is worth being precise about the safety record, because it is often reported more alarmingly than it reads. In the first-in-human study of this superagonist — 33 patients who had relapsed after a stem-cell transplant — no dose-limiting toxicity was identified, and no patient met criteria for severe cytokine-release or capillary-leak syndrome. What did occur was fever and chills with intravenous dosing, an injection-site rash in almost every patient dosed under the skin, and transient hypertension in 83% at the highest doses; responses were seen in 19% of evaluable patients.^[25] The dose-limiting harm belongs to free recombinant IL-15 rather than the superagonist complex. In its first-in-human trial, 18 patients received daily intravenous dosing; severe drops in blood pressure, a fall in platelets and liver-enzyme rises forced a tenfold dose reduction, and the best response achieved was stable disease. Even there the authors record only modest capillary leak, in explicit contrast to high-dose interleukin-2 — the drug whose reputation this one tends to inherit.^[26] These are cancer drugs given to seriously ill patients under close monitoring, not longevity tools; the broader class of unproven anti-aging drugs is covered under geroprotectors.
• Engineered IL-15 cell therapies tether the cytokine to the surface of NK cells so its signal stays local, avoiding systemic leak — a promising idea in experimental cancer immunotherapy, but firmly confined to the lab.^[27]
• Supplements marketed as "exercise mimetics" — beta-alanine, the plant compounds eugenol and octacosanol, and multi-ingredient mitochondrial cocktails — are reported to raise IL-15 or its downstream signalling. The evidence is a single small trial in one case,^[28] an eLife reviewed preprint — not yet a finalised peer-reviewed paper — in mice for the eugenol claim,^[29] and cultured human skin cells for the third — a study of a commercial multi-ingredient supplement.^[30] None demonstrates an immune or longevity benefit in a healthy person. Treat them as research, not advice. The honest summary is that no supplement is a substitute for the muscular work that produces IL-15 the way the body intends.

It is also worth knowing that IL-15 is not benign when dysregulated upward: chronically high local IL-15 is a driver of autoimmune disease, most clearly in celiac disease, where gluten-triggered IL-15 in the gut lining breaks immune tolerance and destroys the intestinal surface.^[31] More is emphatically not better.

What this does and doesn't tell you

What it tells you: immune aging is real, measurable, and partly tractable. The thymus shrinks, NK and T-cell surveillance fades, and the immune system's failure to clear senescent cells feeds the same inflammaging that drives age-related disease. IL-15 is the thread that ties it together — and the organising principle it reveals, that immune cells are rejuvenated by pulses of signalling but exhausted by continuous elevation, explains both why exercise helps and why systemic IL-15 drugs are dangerous. The proven levers are the familiar ones: vigorous, varied exercise first, then sensible energy balance and sleep.

What it doesn't tell you: that any IL-15 drug or supplement is safe or beneficial for a healthy person — chronically raising IL-15 is actively harmful, and the centenarian data showing high IL-15 alongside exceptional longevity is observational, reflecting a whole finely-balanced immune phenotype rather than one molecule you can take. As everywhere in this field, the elegance of the mechanism runs well ahead of the proven interventions, and the proven interventions are the unglamorous ones.

Further reading

• Goyani P, et al. Immunosenescence: Aging and Immune System Decline. Vaccines (Basel) 2024.^[32]
• Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res 2014.^[33]
• Lee H, et al. IL-15 in T-Cell Responses and Immunopathogenesis. Immune Netw 2024.^[34]
• Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett 2010.^[35]
• Yang JY, et al. Natural killer cells: gatekeepers of healthy aging in longevity medicine. Inflamm Regen 2026.^[36]
• Gergues M, et al. Senescence, NK cells, and cancer: navigating the crossroads of aging and disease. Front Immunol 2025.^[37]
• Li Y, et al. IL-15 activates telomerase and minimizes telomere loss and may preserve the replicative life span of memory CD8+ T cells in vitro. J Immunol 2005.^[38]
• Weng J, et al. IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. Oncoimmunology 2016.^[39]
• Gangemi S, et al. Age-related modifications in circulating IL-15 levels in humans. Mediators Inflamm 2005.^[40]
• Tedone E, et al. Telomere length and telomerase activity in T cells are biomarkers of high-performing centenarians. Aging Cell 2019.^[41]
• Zhou L, et al. Centenarians Alleviate Inflammaging by Changing the Ratio and Secretory Phenotypes of T Helper 17 and Regulatory T Cells. Front Pharmacol 2022.^[42]
• Pinti M, et al. A Comprehensive Analysis of Cytokine Network in Centenarians. Int J Mol Sci 2023.^[43]
• Felices M, et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 2018.^[44]
• Crane JD, et al. Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging. Aging Cell 2015.^[45]
• Khalafi M, et al. Interleukin-15 responses to acute and chronic exercise in adults: a systematic review and meta-analysis. Front Immunol 2023.^[46]
• Nadeau L, et al. IL-15 improves skeletal muscle oxidative metabolism and glucose uptake in association with increased respiratory chain supercomplex formation and AMPK pathway activation. Biochim Biophys Acta Gen Subj 2019.^[47]
• Giovannini S, et al. Effects of aging and life-long moderate calorie restriction on IL-15 signaling in the rat white adipose tissue. Eur Rev Med Pharmacol Sci 2020 — rat, n=36, 40% restriction.^[48]
• Sierra APR, et al. Chronic Low or High Nutrient Intake and Myokine Levels. Nutrients 2022.^[49]
• Romee R, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 2018 — n=33; no dose-limiting toxicity, no capillary-leak syndrome.^[50]
• Conlon KC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015 — n=18; the trial where dose-limiting toxicity was observed.^[51]
• Wrangle JM, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 2018 — n=21; no dose-limiting toxicity.^[52]
• Waldmann TA, Miljkovic MD, Conlon KC. Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. J Exp Med 2020.^[53]

---